Therapeutic Targets – Modulation, Inhibition, and Activation

LM Botana (Autor)

Software / Digital Media

494 Seiten

2012
John Wiley & Sons Inc (Hersteller)
978-1-118-18553-7 (ISBN)

Keine Verlagsinformationen verfügbar

Artikel merken

Providing insight into where the next generations of drugs are likely to emerge, this book describes the pharmacology of therapeutically undefined targets and potential applications. In some cases, there are no defined drugs to modulate some of the targets, and in other cases inhibition or activation will render different therapeutic uses. Chapters cover specific biochemical targets like kinases, phosphatases, phosphodiesterases, and potassium channels. Because different diseases can require their own targeting strategies, the book has chapters on the strategies for targeting Alzheimer's, diabetes, pain, and inflammation.

Luis M. Botana was Director of the Department of Pharmacology at the University of Santiago de Compostela (USC), Director of the European Union Reference Laboratory for Marine Biotoxins, and scientific advisor to the drug company LCIFGA. The author of 200 papers and 15 patents, Dr. Botana is the editor of several other books, including Phycotoxins: Chemistry and Biochemistry , published by Wiley (2007). Mabel Loza is Professor of Pharmacology at the University of Santiago de Compostela (USC). She created the USEF Drug Screening Platform, with more than ten years of experience in public and private mixed early drug discovery programs.

Preface vii Contributors ix 1. cAMP-Specific Phosphodiesterases: Modulation, Inhibition, and Activation 1 R. T. Cameron and George S. Baillie 2. Protease-Activated Receptor 2 37 Qihai Gu and Lu-Yuan Lee 3. Voltage-Gated Sodium Channels as Therapeutic Targets 63 Joshua S. Wingerd, Irina Vetter, and Richard J. Lewis 4. Multitarget Drugs for Stabilization of Calcium Cycling and Neuroprotection in Neurodegenerative Diseases and Stroke 123 Antonio M. G. de Diego, Silvia Lorrio, Jesus M. Hernandez-Guijo, Luis Gandia, and Antonio G. Garcia 5. Oligomerization of G-Protein-Coupled Receptors 201 Juan F. Lopez-Gimenez and Javier Gonzalez-Maeso 6. Sigma 1 Receptor Chaperone: Pharmacology and Therapeutic Perspectives 225 Daniel Zamanillo, Enrique Portillo-Salido, Jose Miguel Vela, and Luz Romero 7. Lipids as New Targets 279 Eduardo Domunguez 8. Knowledge Base for Nuclear Receptor Drug Discovery 309 Albert A. Antolin and Jordi Mestres 9. Gene Promoters and Transcription Control Regions as Therapeutic Targets 327 Antonio Zorzano, David Sebastian, Jana Sanchez-Wandelmer, Laia Miret, and Fernando Albericio 10. Roles of Glucagon-Like Peptide and Glucose-Dependent Insolinotropic Polypeptide Hormones in Brain Function and Neurodegeneration 351 Christian Holscher 11. Exocytotic Machinery as a Target for the Development of New Drugs for Schizophrenia 375 Maria Jose Guerrero, Itsaso Hormaeche, Maria Uribarri, Julie Masse, and Jose Maria Palacios 12. Targeting Epigenetic Abnormalities in the Brain 409 Erin Y. Sterner, Lisa E. Kalynchuk, and Hector J. Caruncho 13. Rodent Models as Tools for Discovering Novel Therapeutic Targets in the Brain: The Case of Epilepsy 427 Justin J. Botterill, Axel J. Guskjolen, Lisa E. Kalynchuk, and Hector J. Caruncho 14. New Approaches Applied to Drug Screening 455 Jose Brea and Maria Isabel Loza Index 477

Erscheint lt. Verlag	30.5.2012
Verlagsort	New York
Sprache	englisch
Maße	150 x 250 mm
Gewicht	666 g
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
Themenwelt	Naturwissenschaften ► Chemie
ISBN-10	1-118-18553-6 / 1118185536
ISBN-13	978-1-118-18553-7 / 9781118185537
Zustand	Neuware